Bio-Techne Q4 FY2024: Growth Verticals Advance, Margins Stay in Focus

Transcript intelligence

What changed

Compared with the supplied prior-quarter analysis, organic growth moderated from 2% to 1% even as reported revenue growth remained 2%. The current analysis also emphasized 33.5% adjusted operating margin pressure, versus the prior quarter’s reported sequential expansion to 33%, while the maintained guidance stance and focus on growth platforms continued.

Guidance delta

Guidance sentiment was maintained. Management’s supplied outlook called for low-single-digit organic growth in H1 FY2025 and mid-single-digit growth in H2, with longer-term operating-margin aspirations of 35% to 40%.

Key takeaways

• Revenue grew 2% year over year, while organic revenue grew 1%.
• Four growth verticals represented roughly 45% of revenue; instrument-linked consumables delivered double-digit growth for seven consecutive quarters.
• Molecular diagnostics, led by ExoDx Prostate, produced double-digit organic growth.
• Margin pressure from acquisitions and incentive compensation offset part of the operating progress.

Management priorities

• Scale the Lunaphore diagnostics business and address manufacturing capacity.
• Launch and expand the Leo Simple Western and COMET RNAscope HiPlex platforms.
• Broaden molecular diagnostics, including the exosome-based ESR1 monitoring kit and carrier-screening offerings.
• Develop growth in consumables, GMP reagents, spatial biology and ultrasensitive immunoassays.